Aims/hypothesis In a retrospective, observational, crosssectional, single-centre study, we assessed the prevalence and correlates of different CKD phenotypes (with and without albuminuria) in a large cohort of patients of white ethnicity with type 1 diabetes. 
Introduction
Chronic kidney disease (CKD) is a major complication of diabetes and an independent risk factor for cardiovascular disease (CVD). Albuminuria and reduced GFR are hallmarks of renal damage in individuals with diabetes [1] . In the progression of CKD, albuminuria is commonly believed to precede GFR loss [2] with microalbuminuria being the earliest marker of renal damage [2, 3] . Thus, urinary albumin excretion (UAE) is routinely measured during screening, diagnosis and management of diabetic nephropathy [4] .
Recently, this view has been challenged [5, 6] following identification of individuals with type 2 diabetes who have non-albuminuric renal function impairment [7] [8] [9] [10] [11] . In the UK Prospective Diabetes Study (UKPDS), over a median follow-up of 15 years, about half of the participants who developed renal impairment had no prior albuminuria [12] . Data from the National Health and Nutrition Examination Survey (NHANES) [13] suggest a trend in the change of CKD phenotypes. While the rate of any CKD in individuals with diabetes has not changed over time, the prevalence of an albumin-to-creatinine ratio (ACR) ≥3.4 mg/mmol decreased from 20.8% in 1988-1994 Among these, 24% developed persistent reduction in eGFR while remaining normoalbuminuric [15] . Thus, although AER was associated with eGFR decline in 76% of participants a sustained loss of eGFR could not be identified in 24% of cases.
Microalbuminuria was found to revert to normoalbuminuria in several studies of type 1 diabetes [16] [17] [18] suggesting that the appearance of microalbuminuria does not necessarily signal the start of the progression of diabetic nephropathy [18] . Rather, these findings support the concept of a non-albuminuric CKD phenotype where AER does not progress despite steadily declining GFR [19, 20] . Interestingly, albuminuria and loss of GFR seem to be associated with distinct clusters of specific risk factors, suggesting that the two phenotypes only partly share common pathogenic mechanisms [11, 20] .
Here, we report the results of a retrospective analysis performed in a large cohort of individuals with type 1 diabetes designed to determine the prevalence of CKD phenotypes (i.e. with and without albuminuria), describe associations with other diabetes complications and identify any differences in the associated factors.
Methods
Participants Type 1 diabetes was defined as diagnosis at <36 years with immediate insulin requirement and unbroken insulin need after the initial year since diagnosis [21] . All individuals with type 1 diabetes (n = 843) meeting those criteria who attended the diabetes unit of our institution from 1 January 2001 to 31 December 2009 for screening of complications were eligible for inclusion. Exclusion criteria included pregnancy, non-white ethnicity (n = 32, 4.0%), diabetes duration <1 year (n = 34, 4.0%) and dialysis or renal transplantation. A total of 777 individuals were recruited. The Ethics Committee of the University of Pisa approved the study and consent procedures. Written informed consent was obtained from each participating individual.
All participants underwent a structured interview collecting information about onset of diabetes, its duration, smoking and pharmacological treatments [21] . Body weight, height and waist circumference were measured. BP was measured after 5 min rest in a sitting position, and the average of two measurements (taken 5 min apart) was calculated; hypertension was defined for systolic BP >140 mmHg and/or diastolic BP >80 mmHg and/or use of antihypertensive medication(s). Blood was drawn once, on entry, after overnight fasting for determination of creatinine, HbA 1c , lipids and other variables (see ESM Methods).
Measurements ACR was determined in at least three first-void urine samples obtained at about 1 month intervals in the year preceding recruitment. Urine samples (n = 175, 6.7%) with abnormal sediments (nitrites or ≥250 leucocytes/ml) were discarded. Albumin and creatinine were assayed on the morning of collection.
HbA 1c was measured by HPLC using DCCT-aligned methods [22] . Triacylglycerol, total cholesterol and HDL-cholesterol were determined by enzymatic methods and LDL-cholesterol was calculated using the Friedewald formula [23] . Standard methods were employed for the measurement of the other variables (see ESM Methods).
Definition of renal outcomes Based on the geometric mean of three ACR values the following categories were defined: normoalbuminuria (<3.4 mg/mmol), microalbuminuria or moderately increased albuminuria (3.4-34 mg/mmol) and macroalbuminuria or severely increased albuminuria (≥34 mg/mmol). Normoalbuminuria was subdivided into normal albuminuria (<1.1 mg/mmol) and mildly increased albuminuria (1.1-3.4 mg/mmol) (see ESM Methods).
eGFR was calculated by the Modification of Diet in Renal Disease (MDRD) Study equation [24] and the following categories were identified: category 1, eGFR ≥90; category 2, eGFR 60-89; and category 3, eGFR <60 ml min Assessment of diabetes complications Diabetic retinopathy was assessed by retinal photography [21] and classified according to the Global Diabetic Retinopathy Project Group criteria [26] as non-advanced or advanced, sight-threatening retinopathy. Diabetic neuropathy was assessed with a validated questionnaire [27] and routine screening tests including vibration perception threshold [21] . The presence of previous CVD was determined based on a medical history of all documented major acute events. A 12 lead resting ECG was recorded and coded according to the Minnesota Code [28] . Peripheral vascular disease was assessed by search for femoral and foot pulses and measurement of ankle/brachial ratio (see ESM Methods).
Statistics For this analysis, we first stratified the study population according to AER or eGFR and then assessed the prevalence and implication of CKD stage for each combination of the two. 
Results
The main demographic and clinical characteristics of the study cohort are shown in Table 1 along with current pharmacological treatment.
Clinical characteristics by UAE category Normo-, micro-and macroalbuminuria were found in 712 (91.6%), 50 (6.4%) and 15 (1.9%) participants, respectively. Albuminuric individuals were older and had longer diabetes duration, higher HbA 1c , BMI, systolic and diastolic BP, LDL-cholesterol and triacylglycerol, and lower eGFR (ESM Table 1 ). They also had higher γ-glutamyltransferase (GGT), fibrinogen and uric acid levels. There were more current smokers in the micro-, and fewer in the macro-, compared with the normoalbuminuric groups. Albuminuric individuals were more frequently hypertensive, on BP-lowering agents (and renin-angiotensin system [RAS] blockers) and antiplatelet agents, and had higher daily insulin requirements. Rates of advanced retinopathy, polyneuropathy and CVD increased across the albuminuria categories.
Compared with participants with normal albuminuria (n = 600, 77.2%), those with mildly increased albuminuria (n = 112, 14.4%) had higher HbA 1c and fibrinogen, higher rates of hypertension and advanced retinopathy, and marginally increased rates of CVD. Use of BP-lowering agents and RAS blockers was more common in the group with mildly increased albuminuria (ESM Table 2 ).
Clinical characteristics by eGFR category eGFR categories 1, 2 and 3 included 445 (57.3%), 303 (39.0%) and 29 (3.7%) participants, respectively. Age, diabetes duration and BMI increased progressively across these categories. HbA 1c , systolic and diastolic BP, triacylglycerol, GGT, fibrinogen, uric acid, ACR, rates of treatment with BP-lowering (and RAS blockers), lipid-lowering and antiplatelet agents, and prevalence of hypertension, advanced retinopathy, p o l y n eu r o pa t hy a nd C V D w e r e a l l h i g h e r, a n d HDL-cholesterol lower in eGFR category 3 compared with categories 1 and 2. Categories 1 and 2 showed similar levels for all variables (ESM Table 3 Table 5 ). Interestingly, there were no differences between the phenotypes for the distribution of retinopathy ( Fig. 1) sub-category with mildly-to-severely increased albuminuria were older, had longer diabetes duration, were heavier and had larger waist circumference, and higher HbA 1c Factors associated with different CKD phenotypes The independent association of continuous and categorical Data are expressed as number and percentage
Green, no CKD (n = 695); yellow, stages 1-2 CKD (n = 53); orange, non-albuminuric stages ≥3 CKD (n = 17); red, albuminuric stages ≥3 CKD (n = 12) a Based on the MDRD equation Table 3 Distribution of albuminuric and non-albuminuric phenotypes by eGFR category. CKD phenotypes are defined as for the binary logistic regression analysis described in (Table 5) .
Overall, the sensitivity analysis performed in individuals with eGFR <75 ml min −1 [1.73 m] −2 confirmed the results (Table 5 ).
Discussion
Our results support the emerging view that in type 1 diabetes CKD is more heterogeneous than commonly believed. Even though the Alb + phenotype remains predominant (79.3%), in our cohort more than half of the participants with stage ≥3 CKD (58.6%) displayed the Alb − phenotype. It may also be worth pointing out that the overall prevalence of the Alb − CKD phenotype (2%) is much lower than it has been reported in type 2 diabetes (10%) [11] ; this probably reflects a greater prevalence of hypertension, CVD and obesity in the latter group [11] . These findings are of relevance since most studies investigating the prevalence of non-albuminuric CKD have been performed in type 2 diabetes, where as many as 36% [8] to 62% [10] of individuals with renal insufficiency do Other variables included in model 2 but never selected as significant independent covariates: BMI, smoking habits, diastolic BP, total cholesterol, uric acid, RAS blockers not present with albuminuria. On the contrary, the prevalence of different CKD phenotypes (i.e. with and without albuminuria) and clinical and biochemical factors associated with increasing albuminuria vs decreasing GFR as separate entities have been poorly described in type 1 diabetes. [15] . Similarly, a cross-sectional survey of the UK National Diabetes Audit reported that albuminuria was absent in 54.4% of individuals with type 1 diabetes and stage ≥3 CKD [30] . In our cohort the overall prevalence of normoalbuminuric CKD was 2.2%, similar to that reported in the larger population of the FinnDiane Study (n = 3809, 2.0%) [31] . The two studies, however, differ in that in the FinnDiane Study non-albuminuric CKD accounted for 6.1% of all patients with any CKD phenotype and 15.5% of all individuals with stage ≥3 CKD, while these figures are 20.7% and 58.6%, respectively, in our cohort. These differences are not easy to reconcile but our population is representative of a specific geographical area and reflects clinical management in a single centre as opposed to a population collected at national level and from different centres, which could have introduced more variability. Our results remained substantially unaffected by including individuals with eGFR 60-74 ml min Despite the cross-sectional nature of our study, we speculate that, in a sizeable proportion of the type 1 diabetes population, the decline in GFR can progress without albuminuria or even anticipate its appearance. These results are in line with those of Zerbini et al. [32] who demonstrated, over a 9.5 year follow-up in 146 young individuals with type 1 diabetes, a faster decline in GFR prior to the appearance of microalbuminuria. These observations have prompted the identification of a novel phenotype, the early renal function decline (ERFD), in the development of CKD in type 1 diabetes [33, 34] . Both the First and the Second Joslin Study of Natural History of Microalbuminuria in Type 1 Diabetes reported ERFD (defined as loss in GFR that exceeds 3.3% per year) to evolve in up to 9-10% of normoalbuminuric individuals with type 1 diabetes [33, 35] . Moreover, in the series by Perkins et al. [36] about half of the individuals progressing to advanced CKD experienced only persistent microalbuminuria with some even reverting to normoalbuminuria [36] . These observations are in agreement with our data showing a high proportion of individuals (70.4%) with normal albuminuria (ACR <1.1 mg/mmol) who already had a reduction, although mild, in eGFR (60-74 ml min
). The two phenotypes may also differentiate in terms of outcomes, as ERFD appears to be more frequent in Alb + than in Alb − patients [33, 35] , and the rate of GFR loss tends to be faster in patients with micro-than in those with normoalbuminuria [36, 37] . In summary, our observations and the available evidence support the hypothesis that UAE and loss of GFR may not necessarily represent stages of a common pathway; rather they may be independent markers of progression of the disease [38] . This is further supported by the identification of distinct sets of risk factors for GFR loss vs progression of UAE.
In our cohort, age was an independent predictor in the Alb − but not in the Alb + groups even though there was no difference in age between the two groups within stage ≥3 CKD and CKD stages with eGFR <75 ml min . These findings are in line with reports from the FinnDiane Study [31] and the Second Joslin Study [35] . In the latter, the risk of renal functional decline in normoalbuminuric individuals was independent of HbA 1c quartile, but increased from the lowest to the highest quartile in the microalbuminuric group.
When included in the model, retinopathy, a condition strongly associated with chronic hyperglycaemia, entered in the regression by displacing diabetes duration in stage 1-2 CKD, and HbA 1c in stage ≥3 CKD (Table 4) . History of retinal laser treatment was also associated with both albuminuric and non-albuminuric CKD in the FinnDiane Study [31] .
In our study, all CKD phenotypes were associated with hypertension and/or systolic BP, while no association was found with antihypertensive treatment or specific antihypertensive agents, such as RAS blockers. By indication, use of RAS blockers was more common in patients with stages 1-2 and ≥3 CKD than in individuals with no CKD, with no difference between stage ≥3 CKD Alb + and Alb − phenotypes. In particular, use of RAS blockers was more frequent among patients with eGFR <75 ml min RAS blockage has no effect on non-albuminuric renal insufficiency. In the FinnDiane Study, non-albuminuric CKD was associated with the number of antihypertensive drugs, but not BP levels, antihypertensive treatment or specific renoprotecting antihypertensive agents [31] . In the Second Joslin Study [35] , the risk of decline in renal function increased with systolic BP in both individuals with normo-as well as those with microalbuminuria and, at variance to both the FinnDiane Study [31] and our study, also increased with the number of prescribed nephroprotecting treatments. Increased renal vascular resistance in patients with hypertension can be related to systemic haemodynamics and the presence of subclinical atherosclerosis contributing to the decline in GFR in non-albuminuric CKD [39] . Furthermore, in a study of type 1 diabetes, renal vascular resistance, as reflected by raised systemic vascular stiffness and intraglomerular pressure, was lower in healthy nondiabetic individuals than in normoalbuminuric and microalbuminuric individuals with type 1 diabetes [40] . While uric acid has been proposed as a marker for decline in GFR in people with diabetes more than for progression of albuminuria [19, 37, 41] , we could not find an independent association with any CKD phenotype. On the contrary plasma fibrinogen levels were independently related to the CKD Alb [42, 43] that, in the DCCT/EDIC, was related to albuminuria [44] . Finally, in our cohort, GGT was an independent covariate of stage 1-2 CKD and of stage ≥3 CKD Alb − and Alb + phenotypes, but not in individuals with eGFR <75 ml min . GGT, a marker of cell oxidative stress, has been suggested as a predictor for low-grade albuminuria [45] . In a recent population-based study, the prevalence of albuminuria increased from the lowest to the highest GGT quartile, while eGFR correlated inversely across all GGT quartiles [45] . Moreover, it predicts microvascular and/or renal complications in advanced CKD irrespective of UAE [46, 47] .
Some limitations of our study must be considered. First, this is a single-centre study limited to individuals of white ethnicity. As in many other studies [31, 35] we have no direct measurements of GFR and its estimation was based on a single creatinine measurement. Hence, some individuals may have had temporary reductions in eGFR rather than persistent CKD. This could be especially the case in participants with eGFR 60-74 ml min −1 [1.73 m] −2 .
However, expanding the CKD definition to include this subset of individuals confirmed and strengthened the association with diabetic retinopathy and other covariates, supporting the overall correctness of our phenotype definition. The single assessment of eGFR does not allow us to describe changes over the time, which may be of relevance with respect to spontaneous or drug-mediated remission of microalbuminuria [16] [17] [18] 48] , although the almost universal use of RAS blockers in type 1 diabetes with increased UAE tends to offset the latter. Furthermore, the cross-sectional nature of the study does not allow exploration of the predictive value of different CKD phenotypes for end-stage renal disease, cardiovascular events and all-cause mortality. Interestingly, in the FinnDiane Study [28] , Alb − CKD had the same risk of cardiovascular morbidity and all-cause mortality as patients with the Alb + stage 1-2 CKD, but did not increase the risk of renal outcomes. Finally, our results are based on the MDRD formula for calculation of eGFR. However, the conclusions of our analysis did not change if the CKD-EPI equation was used (data not shown).
In conclusion, we found that non-albuminuric CKD phenotypes are present in a significant proportion of the type 1 diabetes population, in line with previous reports [35] . This challenges the paradigm of renal functional decline following the appearance of albuminuria. Rather, our findings support the hypothesis of two distinct pathways (Alb − and Alb + ) both potentially progressing to advanced kidney disease [38] . This hypothesis is corroborated by the appreciation that distinct covariates relate to the two CKD phenotypes.
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